Abstract | Evidence suggests that the perioperative period and the excision of the primary tumour can promote the development of metastases-the main cause of cancer-related mortality. This Review first presents the assertion that the perioperative timeframe is pivotal in determining long-term cancer outcomes, disproportionally to its short duration (days to weeks). We then analyse the various aspects of surgery, and their consequent paracrine and neuroendocrine responses, which could facilitate the metastatic process by directly affecting malignant tissues, and/or through indirect pathways, such as immunological perturbations. We address the influences of surgery-related anxiety and stress, nutritional status, anaesthetics and analgesics, hypothermia, blood transfusion, tissue damage, and levels of sex hormones, and point at some as probable deleterious factors. Through understanding these processes and reviewing empirical evidence, we provide suggestions for potential new perioperative approaches and interventions aimed at attenuating deleterious processes and ultimately improving treatment outcomes. Specifically, we highlight excess perioperative release of catecholamines and prostaglandins as key deleterious mediators of surgery, and we recommend blockade of these responses during the perioperative period, as well as other low-risk, low-cost interventions. The measures described in this Review could transform the perioperative timeframe from a prominent facilitator of metastatic progression, to a window of opportunity for arresting and/or eliminating residual disease, potentially improving long-term survival rates in patients with cancer.
Introduction
The perioperative period-days before to days-weeks following tumour excision-is short relative to the time span of primary tumour evolvement, or even relative to the timeframe of the metastatic process. Nevertheless, several studies have reported that this short period is critical in determining the risk of postoperative metas tatic disease.
1-3 Although surgeons usually achieve nega tive margins when excising a primary tumour, there is a high risk of residual malignant cells and patients are often treated for potential residual disease (commonly using chemotherapy). Residual tumour cells might be present proximal to the excision location, in the lym phatic system (within positive lymph nodes) or blood circulation, or in distal organs, in the form of single tumour cells or as micrometastases.
Importantly, although surgical excision of a primary solid tumour is crucial and lifesaving, the pro cedure can also facilitate the development of metastases from these residual malignant cells through numerous mechanisms (Figure 1 ). The unavoidable damage to the patients' tissues, and the excision and manipulations of the primary tumour and its vasculature during surgery have been shown to increase shedding of tumour cells into the blood and lymphatic circulations, 4 to increase local and systemic levels of growth factors, 5 and to decrease systemic levels of primarytumourassociated anti angiogenic factors (such as endostatin). 6, 7 Moreover, the patients' paracrine and neuroendocrine responses to surgery, including the release of prostaglandins and catecholamines, can act directly on the primary tumour and residual malignant cells, facilitating malignant cell survival, motility, invasion, proliferation and release of proangiogenic factors, 8 suppress antimetastatic immu nity, 2 and fertilize the microenvironment of residual malignant cells. 9 These prometastatic processes occur simultane ously during the short perioperative period, potentially making this timeframe critical in determining the onco logical outcome. Specifically, it is the synchronization and synergism between these deleterious processes that theoretically renders the patient exceptionally suscep tible to a metastatic disease. 2 For example, increased numbers of circulating malignant cells, combined with moreaggressive and prometastatic characteristics of such cells and suppressed antimetastatic cellmediated immunity, could enable these tumour cells to estab lish metastases in distal organs. Additionally, reduced expression of antiangiogenic factors, alongside surgery induced increases in the levels of growth factors and of proangiogenic compounds, might enable undetectable dormant metastases to undergo the angiogenic switch and quickly grow beyond a critical mass that cannot be controlled.
However, if one can arrest these perioperative pro metastatic processes, then the immediate postoperative period would also become a unique window of oppor tunity to eradicate and/or control residual malignant cells before they adopt characteristics of the former primary tumour, and therefore grow and spread around the body. Specifically, removal of the major bulk of the primary tumour terminates the proinflammatory and/or immuno suppressive effects of many primary tumours, 10 and blocks the ongoing release of malignant cells into the blood and lymphatic circulation. Under such improved conditions, single tumour cells and micrometastases are more easily controlled by cellmediatedimmunity (CMI) than were the primary tumour and the metastatic process, 2 enabling the last residual malignant cells to be eliminated or maintained in a dormant state.
On this basis, the perioperative period should be exploited to reduce metastatic progression and/or to improve oncological outcomes. 1, [11] [12] [13] This period has been relatively unexplored therapeutically, because t raditional chemotherapies and radiation therapies cannot be used during this period, given their suppressive effects on the immune system and/or tissue healing. However, as we discuss in this Review, various other interventions are feasible during this perioperative timeframe, and some hold great promise.
Perioperative physiological responses
The term surgical stress is widely used to describe the hormonal and metabolic changes that follow injury or trauma, including activation of the sympathetic nervous system, the endocrine (corticosteroids) 'stress response' , and the con sequent immunological and haematological changes.
14 Herein, we address not only these responses, but also several additional biological factors that are altered during the perioperative period and have been shown to impact longterm oncological outcomes.
Specifically, tumour excision initiates a cascade of biological perturbations, including local, cellular and neuronal responses, as well as paracrine and endocrine alterations. 15 In addition, environmental challenges that affect the patient in the perioperative timeframe, such as psychological distress, intraoperative hypothermia and administration of anaesthetic agents or blood prod ucts, also trigger a variety of physiological responses that can substantially affect the metastatic process, through effects on distal malignant cells, their microenvironment, and the interacting immunocytes (Figure 1) .
A key role for catecholamines and prostaglandins Catecholamine and prostaglandin levels are commonly increased perioperatively. Catecholamines are abun dantly released due to the patients' anxiety and fear of the disease and the medical procedures. Tissue damage directly induces the local release of prostaglandins, 16 and catecholamine secretion is a prominent neuroendo crine response to tissue damage and the related inflam mation, nociception, and pain. 17 Many tumours also release prostaglandins, or recruit macrophages that do so, 10 presumably to promote tumour vascularization or to suppress immune recognition and destruction. Other soluble factors are also elevated systematically in the peri operative period, including glucocorticoids and opioids. 18 However, their independent role in promoting metastasis seems less consistent.
19
The direct effects of catecholamines and prostaglandins on malignant tissue have only recently been acknowl edged. Many human malignancies express receptors for catecholamines 20 and prostaglandins, 21 and their
Key points
■ The perioperative timeframe-days before and after tumour excision-is pivotal in determining long-term cancer outcomes, disproportionally to its short duration ■ Potential metastasis-promoting aspects of the perioperative period and of surgery include anxiety and stress, specific anaesthetics and analgesics, hypothermia, blood transfusion, tissue damage, specific sex hormones, nociception and pain ■ Deleterious processes include excess and maladaptive perioperative responses at the paracrine, endocrine, and immune-system levels ■ Potential novel interventions include specified modifications to surgical procedures, stress-reducing and anti-inflammatory approaches, such as perioperative administration of non-selective β-adrenergic blockers and COX2 inhibitors, and perioperative immune stimulation ■ These interventions could transform the perioperative timeframe from being a prominent facilitator of metastatic progression, to a yet unexplored opportunity for arresting and/or eliminating residual disease Nature Reviews | Clinical Oncology Figure 1 | A schematic presentation of major perioperative risk factors for tumour progression, and some of the neuroendocrine, paracrine, immunological, and angiogenic perturbations they elicit. These perturbations are mutually interactive and eventually affect malignant cells through directly interacting with them and/or through impacting their surrounding milieu.
REVIEWS
activation can promote the metastatic potential of the tumour through several molecular mechanisms, including the promotion of tumourcell proliferation, 22,23 adhesion, 24 locomotion, 25 extracellular matrix invasion, 22 resistance to apoptosis and anoikis, [26] [27] [28] and secretion of proangio genic factors such as vascular endothelial growth factor (VEGF). [29] [30] [31] These processes are critical for the meta static dissemination and growth of malignant tissue; thus, a ttenuating them might preclude m etastatic outbreak.
The indirect effects of catecholamines and prosta glandins are mediated through various mechanisms, including the perioperative suppression of antimetastatic immunity (see 'Immunosuppression and cancer recur rence' section), 15, 18, [32] [33] [34] [35] [36] [37] tumourpromoting alterations in the microenvironment of the residual malignant cells, 8 and potential stimulation of lymphaticmediated spread of malignant cells (Sloan, E. personal communication).
Immunosuppression and cancer recurrence
The claim that suppression of CMI promotes the meta static process relies on the assumption that CMI-for example, cytotoxicity mediated by natural killer (NK) cell or cytotoxic T lymphocyte (CTL)-encompasses antimetastatic capacities. Studies performed in animal models provide unequivocal evidence in support of such a role for various immunocytes, including CTLs, NK cells, macro phages, and dendritic cells. 15 For example, NK cells are able to identify and kill malignant cells, inducing apoptosis through the perforinegranzyme and deathreceptor pathways. 38 Accordingly, rodents with a deficient NKcell system develop more tumours and metastases than do naive animals, [39] [40] [41] and rats in which NK cells were depleted showed greater lung retention of syngeneic cancer ous cells (following their intra venous administration) and increased numbers of metastatic foci. [42] [43] [44] Importantly, almost all leukocytes express receptors for catecholamines and prostaglandins, 45, 46 and similar to most other aspects of CMI, NK cells are directly inhibited by catecholamines and prostaglandins; 47 this i nhibition has been shown to exacerbate the metastatic process in animal models. 34, 44 In clinical studies in patients with cancer, which provide outcomes of a less causal nature compared with animal studies, but hold greater validity, ample evidence indicates an important role for CMI in controlling the metastatic process. Specifically, clinical studies have revealed that the immune system extensively interacts with developing primary tumours, metastasizing cells, and established metastases, leading to recognition and killing of many malignant cells, but eventually sparing tumour foci that have adopted effective immuneescape mechanisms-a process that is now termed 'immuno editing' . 48 Attesting to these processes in patients with cancer, and to the significant deleterious consequences of immunosuppression are: the numerous immune escape mechanisms revealed in human malignancies; 10 the finding that in vitro mixed lymphocyte response against excised autologous breast tumours predicts long term survival rates better than tumour stage and grade; 49 the increased frequency of certain malignancies, and the dramatic increase in metastatic development in patients immunocompromised by various aetiologies (compared with patients with intact immune systems); 50, 51 and the promising outcomes of FDAapproved immunebased therapies, including the cancer vaccine sipuleucelT, 52 the CTLA4 receptor blocker ipilimumab (which enhances Tcell mediated antitumour immunity and increases sur vival), 53 and antiPD1 and antiPDL1 antibodies with promising clinical activity in several tumour types. 54 Recent findings further resolve prior reservations regarding the antimetastatic capacities of CMI. Several unique leukocyte populations were identified in vivo, in both rodents and humans, which had a remarkable ability to recognize and kill autologous tumour cells that were traditionally considered 'immuneresistant' , includ ing type1 natural killer T (NKT) cells, 55 marginating pulmonary leukocytes and their subpopulation of activated NK cells, 56, 57 liver pit cells (activated NK cells in hepatic sinusoids), 58 dendritic epidermal T cells, 59 and killerdendritic cells. 60 These cell populations resemble in-vitroactivated lymphocytes in terms of their height ened cytotoxic activity and geneexpression profile, but exist endogenously without immune stimulation.
2 Their capacity to kill autologous tumour cells far exceeds the capacity of traditionally studied circulating leuko cytes.
2 Furthermore, most of these unique leukocytes are strategic ally located in capillaries of major organs (such as the lungs) that filter all circulating blood and foster close contacts with circulating malignant cells, thus enabling efficient recognition and destruction of these aberrant cells.
2 In addition, most of these unique leuko cyte populations, including marginatingpulmonary leukocytes, 35, 56, 61, 62 type1 NKT cells, 63 and dendritic epi dermal T cells, 64 have been shown to be suppressed by catecholamines and/or prostaglandins. Thus, all these studies clearly indicate that intact immunity is an impor tant factor in controlling the metastatic process, bearing a greater role in this regard than previously assumed. 65 
Surgical aspects affecting recurrence
The perioperative period in patients undergoing onco logical surgery is characterized by countless and varying factors; of note, each of these factors can alter oncological outcomes. In this Review we focus on those factors that are directly affected by surgery and/or by interventions or events occurring during the perioperative period. Even though preexisting factors such as comorbidities, performance status, and body mass index can influence oncological outcomes substantially, 66, 67 they are beyond the scope of this Review.
Anaesthetic and analgesic approaches
The choice of anaesthetic and analgesic approach used during surgery and the perioperative period has long been proposed to influence cancer recurrence. 68 In general, it seems that both general anaesthesia and the use of con siderable quantities of opioid analgesics often increase recurrence rates. 69 By contrast, efficient pain alleviation through the use of local or regional anaesthesia-analgesia , with or instead of general anaesthesia, might improve longterm cancer outcomes.
12,13 Unfortunately, the avail able evidence regarding the effects of specific anaesthetic and analgesic agents and techniques, as well as the mecha nisms mediating their alleged effects on cancer outcomes, are inconclusive. [70] [71] [72] The question of whether regional anaesthesia-analgesia could indeed improve oncologi cal outcomes remains unresolved, as none of the afore mentioned studies that failed to support this hypothesis had the statistic power to detect effects smaller than a 33% improvement in recurrencefree survival. Furthermore, most studies addressing this issue were retrospective, and some had unavoidable methodological limitations, which potentially hindered their ability to pinpoint the effects of regional anaesthesia-analgesia. Several larger clinical trials are ongoing (NCT00684229, NCT00418457, NCT01179308), [73] [74] [75] and might yield moredefinitive data. Anaesthetic agents can directly influence the malig nant tissue and its cellular microenvironment, 76 and can affect the neuroendocrine system and the immune system in complex manners; thus, it is likely that s p ecific agents and approaches will have complex and poten tially opposing effects, depending on circumstances, [77] [78] [79] and the choice of anaesthetic and analgesic approaches should be planned carefully in conjunction with other aspects of surgery, based on the following considerations.
First, high doses of opiates have been mostly shown (in animals and/or humans) to activate stress responses, suppress antimetastatic CMI, increase angiogenesis, increase prometastatic characteristics of tumour cells, and promote progression of metastases. 76, [78] [79] [80] [81] Second, suppression of pain and nociception through the use of nonopiate agents, such as tramadol, cyclo oxygenase (COX) inhibitors, or low doses of opiate drugs, such as fentanyl, has been demon strated to reduce stress responses and sympathetic activity in patients, and seems to decrease metastasis in murine models. 82, 83 Of note, the use of COX inhibition might be a crucial addition to such intervention, which could help to maximize the benefits in the context of tissue damage and residual malignant cells. 36 Third, the use of volatile and nonvolatile anaesthetics that activate the sympathetic nervous system and/or adrenergic receptors (for example, ketamine, but not propofol) has been associ ated with increased metastatic progression in rodents through stimulation of adrenergic responses. 78, 84, 85 Finally, regional anaesthesia and spinal blockade in patients with cancer efficiently reduce intraoperative and post operative sympathetic responses, and were shown to either mark edly improve longterm cancer outcomes, 12, 13, 86, 87 or to have no effect, [70] [71] [72] 86 but never to worsen outcomes. 68, 88 Therefore, until further evidence is obtained through dedicated clinical trials, when feasible it seems favourable to replace general anaesthesia and opiates with regional anaesthesia-analgesia, tramadol, and/or nonopiate a nalgesics, or to add regional anaesthesia-analgesia to general anaesthesia when operating on patients with cancer, while also ensuring adequate pain control.
Blood transfusion
Blood transfusion, often required during surgery, has been repeatedly shown to cause immunosuppression or immune perturbations 89 through increase in prosta glandin production 90 and other physiological alterations, which lead to suppression of NK activity 91 and ineffi cient immune reactivity or immune tolerance. 92 These physiological and immunological m odulations were suggested to underlie the increase in cancer mortal ity rates associated with blood transfusion, which was reported in several types of cancer and repeatedly in color ectal cancer. 93 How ever, the medical circumstances that necessitate blood transfusion, rather than the pro cedure itself, could be the cause of the increased cancer mortality, as all clinical studies testing the effect of blood transfusion are naturally cohort studies (most are retro spective), as one cannot randomize patients to receive or not receive blood transfusion. To overcome this methodo logical obstacle, several studies incorporated designs that took into account all known potential con founders (such as tumour stage and duration of surgery), and nevertheless reached the same conclusion in terms of cancer m ortality-that is, that the transfusion has an i ndependent d eleterious influence. [94] [95] [96] Of note, studies also indicated an advantage for spe cific transfusion protocols. 96 For example, the transfusion of packed red blood cells, rather than whole blood, was shown to minimize the deleterious effects of the trans fusion 92 (also in a prospective study 91 ), suggesting that transfused allogeneic leukocytes might constitute addi tional targets for the host's immune system, a potential source of transfused bloodrelated immunosuppressive factors, and an additional cause for host perioperative stress responses. The number of blood units transfused has been unequivocally correlated with survival rates, even when adjusting for other risk factors. 97, 98 Beyond the specific constituents of the transfused blood, other factors, such as the storage of the blood cells, also have an impact on oncological outcomes. Indeed, it has been shown in rodents that the use of erythrocytes stored beyond nine days before transfusion increased suscepti bility to various circulating malignant cells, whereas the storage interval of allogeneic leukocytes or their secreted factors had only a minor impact. 99 These un desirable effects of transfused erythrocytes were restricted to a short posttransfusion perioperative period, and can be explained by exhaustion of host antimetastatic immuno cytes (such as NK cells) that are diverted and saturated by the countless transfused deteriorating erythrocytes. 99 Overall, it seems advantageous to reduce the likelihood of a blood transfusion by using bloodless surgery tech niques, 100, 101 minimizing the number of blood units trans fused, and/or using packed red cells instead of whole blood for the transfusion itself. The optimal storage i nterval of the transfused blood should be evaluated clinically.
Hypothermia
Mild perioperative hypothermia (up to a 2 °C decrease from the normal body temperature), which is com monly caused by surgery, 102 has immunosuppressive and other maladaptive consequences. For example, 24 h after surgery, hypothermia results in reduced produc tion of IL1β and IL2, suppressed mitogeninduced lymphocyte proliferation, and elevated cortisol levels. 103 Furthermore, hypothermia also activates the sympathetic nervous system (SNS), leading to elevated noradrenaline levels, 104 and potentiates the requirement for blood trans fusion, owing to impairment in platelet function and in the coagulation cascade. 105 Overall, considering that hypothermia causes per turbations in various physiological indices and results in deleterious clinical outcomes, 106 it should also be suspected to worsen cancer prognosis. Indeed, in a rat model of colon cancer, tumour growth was increased by perioperative hypothermia, 107 and severe hypothermia (3-7 °C decrease from the normal body temperature) markedly suppressed NKcell activity and jeopardized host resistance to experimental mammary metastasis, effects that were attenuated by βadrenergic blockade. 85 However, no sufficiently powered clinical studies or randomized trials have been conducted to elucidate the influence of hypothermia on cancer recurrence.
Maintaining normothermia during surgery is, now a days, mandatory in most medical centres; however in some hospitals at which such a requirement is not imple mented, we recommend to strictly avoid hypothermia in patients undergoing tumour resection.
Laparoscopy, open surgery, and tissue damage Numerous studies have indicated the beneficial effects of laparoscopy compared with open surgery on several shortterm clinical outcomes in various types of surgery (oncological and nononcological), including shorter durations of hospitalization, reduced postoperative pain and use of pain medication, and reduced blood loss and need for transfusions. [108] [109] [110] [111] However, the evidence for improved immune and endocrine status following laparoscopy is less convinc ing. For example, whereas several randomized clinical trials (RCTs) indicated lower IL6 levels follow ing laparo scopy, 112, 113 alterations in other key cytokines, includ ing the immunosuppressive IL10, are not clear, 114, 115 neither are the effects on the number of circulating NK cells 112, [116] [117] [118] and hormonal stress responses. 117, 119 The lack of clear advantages for laparo scopic procedures according to these indices might be related to the morecomple x nature of laparoscopic procedures, especially with regard to abdominal oncological surgeries. For example, laparo scopy for colorectal cancer often necessitates more extensive manipulations of internal organs and prolonged surgical duration; such surgery might have similar effects to an open abdominal surgery due to 'ceiling effects' in endocrine and immunological indices. 117 More importantly, and not surprisingly given the above, oncological outcomes seem least affected by surgery type. Although a RCT in patients with colon cancer reported that laparoscopic surgery resulted in improved longterm cancer outcomes, 120 most RCTs have not shown significant differences in longterm outcomes, as reviewed in regard to colorectal, 121 endometrial 122 and ovarian 123 cancers. Similarly, studies in our animal models, showed that adding laparotomy to a minor surgical procedure, or performing a moretraumatic surgery to excise a primary tumour 36 or administer syngeneic malignant cells, 124 resulted in worse immune outcomes, but did not signifi cantly worsen cancer outcomes. Furthermore, in these studies, the use of a nonselective βadrenergic antago nist and a COX2 inhibitor to attenuate the responses to surgery resulted in a similar degree of improvement in cancer outcomes (including overall survival rates) in minor and major surgical procedures. 36, 125 These findings support the ceilingeffect hypothesis and the potential clinical benefits of perioperative interventions, such as COX2 inhibition and βadrenergic blockade, both in minor and in major procedures.
On this basis, the priority of every surgeon should be to achieve complete excision of primary tumours (nega tive margins) and all evident or suspected metastatic foci, even at the expense of extending tissue damage and surgical trauma. Of note, the specific blockade of excess responses to surgery should be considered irrespective of the type of surgery.
Sex hormones and surgical responses in women
For decades, the phase of the menstrual cycle and the levels of sex hormones during surgery in premenopau sal and in postmenopausal women have been subject of debate in terms of their impact on longterm cancer out comes in women with breast cancer. [126] [127] [128] [129] One hypoth esis is that high oestrogen levels concurrently with low progesterone levels is a major risk factor for metastatic progression, 127 possibly because this hormonal pattern promotes a greater immunosuppression. 130 Indeed, a recent pivotal RCT in 1,000 women with breast cancer showed that a single preoperative administration of hydroxyprogesterone (a synthetic progesterone), which disrupts this hormonal pattern, substantially reduced recurrence rates in lymphnodepositive patients, but not in lymphnodenegative patients.
11
The findings of this RCT indicate the causal impact of sex hormones on cancer outcomes in a context of surgical tumour excision, and thus also suggest that the relatively minor surgery for breast cancer excision can have pro found effects on the metastatic process.
11 Specifically, we believe that the fact that a specific temporary hormonal status on the day of surgery has a considerable longlasting impact indicates that either surgery dramatically potenti ates an effect of sex hormones, or that sex hormones mod ulate the profound effects of surgery-highlighting the key influence of biological factors during the periopera tive period in determining cancer outcome. Furthermore, we suggest that the underlying mechanism is a facilitation of a preexisting metastatic process by surgery. This asser tion is supported by several characteristics of the RCT and other studies indicating the perioperative effects of sex hormones on cancer outcomes, specifically, that they were observed in women with positive but not negative lymph nodes, were due to distal malignant recurrence, were not evident before 3 years postsurgery, and were independent of tumour hormone receptor status.
11, 128 These observa tions suggest that surgery potentiated an ongoing meta static process, not through direct effects of sex hormones on the malignant tissue (as it was independent of recep tor status), but through an indirect mechanism, such as immuno suppression 131, 132 or other processes that facilitate p rogression of an early stage of a metastatic process.
11,127
To simulate this phenomenon, we used a rat model of mammary adenocarcinoma metastasis, and directly showed that the influence of hormonal/oestrous status occurs in the context of surgery or βadrenoceptor stimu lation, but not in their absence. 131, 133 Similarly, in vitro the levels of βadrenergic suppression of cytotoxic activity of NK cells harvested from both women and rats were dependent on the menstrual/oestrous phase during which blood was withdrawn. [131] [132] [133] These results directly indicate that the menstrual and oestrous cycles modulate the susceptibility of NK cells to suppression by adrena line or noradrenaline, which might stem from the find ings that sex hormones modulate the expression levels of a drenergic receptors on lymphocytes and NK cells. 134 Overall, because it might not be clinically practi cal to restrict surgery for women with a specific sex hormone status, 135 and as most oncological patients are postmenopausal , one might consider progester one administration and/or βadrenergic blockade as prophylactic measures.
11
Psychological stress Patients with cancer are naturally subject to emotional distress, 136, 137 from cancer diagnosis, through opera tion and adjuvant therapies (that also generate concerns about body deformation especially in patients with breast cancer), and continuing for years, owing to the ongoing struggles and fears of social isolation, disease recur rence, and death. Of note, psychological factors, such as stress and anxiety, trigger marked endocrinological and immunological responses, which during the peri operative and following periods could influence cancer progression and longterm survival rates, similarly to the effects of physiological factors. Indeed, stress responses that are not related to tissue damage were reported as risk factors for metastatic progression in numerous animal studies, 47, 138 and also in some clinical trials. [139] [140] [141] Specifically, patients who expressed high subjective stress levels when first diagnosed with cancer exhib ited lower levels of NKcell activity. 142, 143 Moreover, the quality of emotional support received by the patients was the main predictor of NKcell cytotoxicity once patients were discharged from hospital. 144 Not surprisingly, there fore, the management of cognitivebehavioural stress was efficient in decreasing systemic cortisol levels 145 and in reducing proinflammatory gene expression in circulating leukocytes. 146 Nevertheless, psychological interventions in patients with cancer do not seem to reliably improve longterm oncological outcomes. [139] [140] [141] [147] [148] [149] Inconsistent findings, and the overall scarcity of positive outcomes, despite decades of research, suggest a moderate or lack of improvement in longterm cancer outcomes by common psychological interventions.
We suggest that, although stress is predominant throughout the disease, its influence on survival occurs mainly during the short perioperative timeframe, which rarely includes psychological interventions. Indeed, psycho logical therapy provided solely throughout hos pital ization has been shown to result in improved sur vival rates, 140 whereas postsurgical therapy did not. 148, 149 Furthermore, because both psychological and physiologi cal factors activate most neuroendocrine stress responses perioperatively, interventions to circumvent only the psychological stress could be insufficient, and would be less effective than pharmacological interventions, such as administration of βblockers, that are expected to counteract stress responses of any origin-emotional or physiological. We, therefore, encourage psychological interven tions throughout the disease timeframe, especially peri operatively, if feasible. However, during the peri operative period, psychological interventions cannot replace pharmaco logical interventions, and should be introduced carefully without burdening patients with responsibility for their own stress responses.
Nutritional status and nutritional support
Nutritional interventions have been repeatedly shown to affect immediate postsurgical outcomes; 150 however, their role in determining oncological outcomes remains unclear. On the one hand, reports from preclinical studies have raised concerns that excessive nutritional support, and specifically parenteral nutrition, could potentially lead to worse oncological outcomes by facili tating tumourcell proliferation. 150 On the other hand, nutritional deficiencies, manifested as low pretreatment levels of serum albumin, have been repeatedly linked to worse oncological outcomes in gastrointestinal, lung, g ynaecological, and other malignancies. 151 Only one randomized trial has tested the effects of a nutritional intervention on oncological outcomes beyond the duration of the postsurgical hospitalization; in this study of 32 patients, perioperative arginine supplements markedly improved longterm survival of malnourished patients with head and neck cancer from a median of 20.7 months to 34.8 months. 152 A comprehensive multi centre prospective cohort study assessing the relationship between nutrition, lifestyle factors, and colorectalcancer recurrence is ongoing (the COLON study). 153 Potential perioperative interventions β-adrenergic blockers and COX2 inhibitors As indicated throughout this Review, a variety of peri operative processes that are associated with increased risk for cancer recurrence are triggered through excess release of catecholamines and/or prostaglandins. Indeed, both animal studies and clinical retrospective studies suggest that their blockade can be an efficient t herapeutic approach.
In animal models involving xenograft of human malig nancies or syngeneic cancer cell lines, the use of the nonselective βadrenergic blocker propranolol, and the selective COX2 inhibitor etodolac resulted in reduced endocrine 36 and angiogenic 154 perturbations, improved antimetastatic immunity, 35 ,36 attenuated surgeryinduced potentiation of metastasis, 36, 125, 154 and improved long term survival rates. 36 In some studies, only the com bined use of the two drugs was effective, 35, 36 which can be attributed to the abundance of both catecho lamines and prostaglandins during the perioperative period, in conjuncture with redundancy in their impact on intra cellular cascades in immunocytes (both activate the cAMP-PKA pathway) and redundancy in their impact on proangiogenic processes.
12
In humans, the chronic use of COX inhibitors or of βblockers in healthy peoples is an efficient chemo preventive measure against the formation of primary tumours of various origins, 155 including the breast and colon. 156, 157 Moreover, regular users of nonselective βblockers (for example, those treated for blood pres sure), in whom epithelial ovarian, primary peritoneal, or fallopiantube cancers have been diagnosed, exhibited a markedly prolonged survival period. 158 The clinical use of such drugs only during the peri operative timeframe has been less frequently studied, but nevertheless yielded promising results. A low daily dose of the COXinhibitor aspirin (25-50 mg per day) during the first postoperative year in patients with gastric and oesophageal cancer markedly improved 5year survival rate, but only in patients with lowstage nondisseminated malignancies. 159 Three RCTs studied the shortterm effects of COX2 inhibition (2-4 weeks before surgery) on tumour character istics, in stage I-II primary breast cancer, 160 invasive transitionalcell carcinoma, 161 or pros tate cancer. 162 The first two studies exhibited a modest increase in tumourcell apoptosis, 160, 161 whereas the third study also indicated a reduction in tumourcell prolifera tion, microvessel density, angiogenesis and expression of the hypoxia inducible factor (HIF)1α. 162 A retro spective study showed improved survival rates after intra operative administration of a nonselective COX inhibitor, ketorolac, in patients under going surgery for breast or lung cancer (but not kidney cancer). 163 Furthermore, the use of βblockers for several months before surgery, along with neoadjuvant therapy, in patients with triplenegative breast cancer, was associated with improved recurrence free survival. 164 In patients with malignant nonmetasta sized melanoma, the treatment with βblockers was predictive of a reduced cancerrelated and allcause mortality, even when initiated ≤90 days before diagnosis and/or surgery, 165 but only in nonmetastasized disease. Together, these results suggest that treatment with βblockers is indeed effective in controlling the initial stages of the metastatic process.
As discussed above, regional anaesthesia that is added to general anaesthesia reduces sympathetic responses, and can thus be considered also as an antisympathetic inter vention. Notably in the two studies that showed improved oncological outcomes when adding regional anaesthesia to general anaesthesia, 12,13 the therapeutic protocol for all patients included treatment with a COX inhibitor during surgery, further supporting the suggestion of synergistic effects of adrenergic blockade and COX inhibition.
Ultimately, we suggest that a combined use of an ad renergic blocker and a selective COX2 inhibitor, initiated a few days before surgery and continuing for a few weeks postoperatively (or longer), could result in a substantial decreases in cancer recurrence and in improved overall survival rates. The safety of this drug combination, in terms of tissue healing, has been shown in rats, 166 and we have now initiated two pilot RCTs testing the perioperative use of propranolol and etodolac in patients with colorectal and breast cancer (NCT00888797, NCT00502684).
167,168
Statins and omega-3 Statins are a widely used group of lipidlowering drugs; they inhibit the enzyme HMGCoA, which has a major role in cholesterol formation in the liver. Omega3 fatty acids are present in high concentration in several foods, including fish, and are used as a food supplement that can reduce blood levels of triglycerides. 169 Both statins and omega3 fatty acids have been suggested as cancer chemopreventive agents, as well as antiinflammatory treatments in the context of nononcological and onco logical surgeries, [170] [171] [172] which could potentially reduce postoperative growth of residual malignant cells. 173 In a populationbased study in Denmark that assessed mortality among 295,925 patients with cancer, reduced cancerrelated mortality was observed in patients treated regularly with statins in 13 of 27 cancer types analysed, 174 particularly in prostate and colorectal cancers, but not in melanoma, as also shown by others. [175] [176] [177] In a pio neering RCT in patients with hepatocellular carcinoma, daily statin treatment for 16.5 months ± 9.8 months after transcatheter arterial chemoembolization resulted in a doubling in survival duration. 178 Further more, in rats injected with lymphoma cells, statin treatment markedly decreased the formation of metastases, but not the growth of the primary tumour. 179 Additionally, treatment of patients with highgrade breast cancer with statins for a few weeks preoperatively resulted in decreased levels of tumour proliferation markers and increased levels of apoptotic markers, 180 suggesting reduced metastatic growth. 181, 182 The use of omega3 fatty acids was associated with clinically relevant attenuation of postoperative immuno suppression and infection, [183] [184] [185] [186] and increases the res ponse rate to chemotherapy and 1year survival among patients with advanced nonsmallcell lung cancer. 187 Omega3 fatty acids also increased resistance to experimental and spontaneous metastasis, and increased r ecurrencefree survival following excision of m etastasizing primary tumours in animal models. 186, 188 Several biological mechanisms could underlie the beneficial oncological effects of omega3 and statins. 189 First, both statins and omega3 have wellestablished overall antiinflammatory effects, that are translated into reduced systemic levels of Creactive protein, 190, 191 an in vitro shift towards type2 T helper cell (T H 2) domi nance, 192 and reduced lipopolysaccharideinduced IL6 production. 193 Furthermore, longchain omega3 fatty acids are known to decrease the production of inflam matory cytokines, eicosanoids, and prostaglandins. 189 Second, at clinically relevant concentrations, 194 statins have been shown to arrest tumourcell growth 195 and to induce apoptosis in the majority of tumourderived cell lines tested in vitro, including neuroblastoma, juve nile monomyelocytic l eukaemia, and some breast and p rostate carcinomas. [196] [197] [198] Interestingly, statins have a synergistic effect with COX inhibitors 199 that, in vitro, leads to G0-G1 phase cell cycle arrest 200 and to enhanced apoptosis in several cell lines. 200, 201 Further more, administration of these drugs in vivo following injection of malignant cells into rodents delayed tumour formation and reduced tumour volume. 201, 202 In conclusion, prolonged use of statins or omega3 might reduce the prevalence of some types of cancer. Of note, the perioperative administration of these drugs is likely to exert beneficial effects by minimizing the metastatic process, effects that might synergize with the impact of NSAIDs, including COX2 inhibitors. Such safe and inexpensive approaches should be evaluated in clinical studies.
Perioperative immune stimulation
Early approaches to immune stimulation were based on cytokine delivery (IL2, IL12, or IFNα), and although efficient in attenuating metastases in animal models 203 and in some clinical studies, 204 this method caused severe systemic adverse responses, including pyrogenic effects indistinguishable from signs of infections. 204 Therefore, such approaches are rarely considered for perioperative use, despite the acknowledged capacity of the immune system to attenuate the metastatic process. However, some synthetic agents that trigger endo genous immune responses have recently been approved by the FDA, and were shown to induce effective, self limited, balanced, multicytokine responses with minimal adverse effects. One such agent is the Tolllike receptor (TLR)9 agonist, class C CpG oligodeoxynucleotide (CpG), which activates NK cells, B cells, and plasma cytoid dendritic cells. 205 In mice, CpG was shown to have both cancer preventive and therapeutic effects, [206] [207] [208] and in rats, was demonstrated to diminish metastatic progres sion when injected one day before surgery. 209 In the clinic, CpG is being tested as an adjuvant to chemotherapeutic agents in several cancer types, 210, 211 but has not been tested in the perioperative context. A morerecently introduced agent is the TLR4 agonist, glucopyranosyl lipid adjuvant (GLA), which activates T cells and dendritic cells. This compound is safe as an influenza vaccine adjuvant, 212 and ongoing studies testing the effect of this compound on cancer progression in the p erioperative context in animal models are promising. 213 Despite these encouraging data, several obstacles to effective and safe perioperative use of immune stimula tion should be circumvented. Animal studies have shown that stress exposure alongside immune stimulation with IL12 or CpG counteracted the beneficial effects of these agents on antimetastatic immune activity. 61, 62 Such stress responses, which occur naturally in patients with cancer but not in animal models, might partly explain the dis crepancy between the promising results of immune stimu lation exhibited in animal models and the moremodest success of this approach in clinical trials. Moreover, even when effective immune stimulation is achieved, surgery and/or psychological stress can markedly suppress immu nity, rendering immune stimulation ineffective in the peri operative context. 214 To overcome these obstacles, we have combined preoperative immune stimulation (with CpG, IL12, or polyinosinepolycytidylic acid) with βblocker and/or a COX2 inhibitor in several animal models, and found that this integrative approach is markedly more effective than using each of these interventions alone. 43, 203 Importantly, some immunestimulating agents can directly or indirectly potentiate tumour progression, as was shown with respect to granulocytemacrophage colony stimulating factor (GMCSF). 215 Such adverse effects can be mediated by specific prometastatic cytokines, stress hormones known to be induced by immune stimulators, or by preoperative selection of resistant tumour cells as a result of too early and p rolonged p reoperative immune activation. Animal: a study with progesterone showed positive outcomes Human: none RCT: positive effect for hydroxyprogesterone injection in patients with lymph-node-positive breast cancer (n = 1,000)
*Animal refers to studies in animal models of cancer; human refers to retrospective, and prospective nonrandomized studies; and RCT refers to randomized clinical trials. Abbreviations: COX2, cyclooxygenase-2; GI, gastrointestinal; NA, not applicable; RCT, randomized clinical trial; TACE, transcatheter arterial chemoembolization; TLR, Toll-like receptors.
Enhanced recovery after surgery The effects of numerous perioperative interventions on immediate postsurgical outcomes have been studied extensively over the years. The results from these studies have been analysed and integrated into Enhanced Recovery After Surgery (ERAS) guidelines in various surgical arenas. 216 ERAS is an evidencebased, compre hensive, multimodal approach designed to achieve early recovery for patients undergoing major surgery. Despite outstanding results in the immediate postsurgical set tings, with up to a 50% reduction in postoperative com plications, and a 30% reduction in care time, [217] [218] [219] no study has yet reported the oncological outcomes of these new approaches. As ERAS guidelines often overlap with the principles presented herein to limit the deleterious effects of surgeries on cancer recurrence (for example, minimizing the systemic use of opiates), it is our recom mendation to evaluate each guideline based on the recommendations presented herein, and, if no contra dictions found, to incorporate them in c onjunction with studying oncological outcomes.
Conclusions
Ample evidence suggests that some biological perturba tions during the critical perioperative period can mark edly alter metastatic progression, and consequently affect longterm oncological outcomes. Having identi fied some surgical factors and their endocrine medi ators, physicians can now use this knowledge to initiate muchneeded clinical research to prevent such deleteri ous effects through short and safe perioperative interven tions. Tables 1 and 2 summarize our recommendations on how one could implement such an approach in routine practice or clinical trials. Clearly, it is necessary to tailor potential interventions to specific cancer surger ies and patient character istics. One should also strive to eliminate as many deleterious aspects of surgery as pos sible due to multiple converging responses to surgery. Of note, many of the discussed surgical aspects affect cancer progression by inducing unnecessarily profound stress and inflammatory responses. Accordingly, a combined nonselective βadrenergic blockade and COX2 inhibition approach, which is safe and effective, could be used in the clinic during the perioperative timeframe. Importantly, the malignant tissue continuously mutates, 220 and with time and increasing selective pressure develops more effective escape mechanisms. Thus, it would theoretically be favourable to initiate new antimetastatic interventions as late as possible before surgery, rather than as early as possible, to refrain from inducing a moreresistant tumour and micrometastases before surgery. Such inter ventions should be continued for at least few days or even weeks postoperatively to overlap and counteract physio logical perturbations induced by surgery. On the basis of the limited relevant clinical literature, it seems that the proposed interventions would be more effective in patients without overt preexisting metastases, but this suggestion should be tested. Finally, it should be noted that the perioperative period is generally underused therapeutically, as most standard neoadjuvant or adju vant therapies are contraindicated immediately before or after surgery. Our therapeutic recommendations use this critical gap in treatment as a window of opportunity for safe and inexpensive interventions that might sub stantially affect cancer progression, potentially increasing survival rates in patients with cancer. 
